Compare Cytokinetics Inc (CYTK) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Ryanair Holdings plc — how do they compare? Cytokinetics Inc trades at $62.64 (market cap $8.62B), while Ryanair Holdings plc trades at $53.11 (market cap $27.11B). The key difference: Ryanair Holdings plc is far larger — about 3.1× Cytokinetics Inc's market cap, and Ryanair Holdings plc pays a 1.66% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Ryanair Holdings plc for 72 Days on average.
| CYTK | RYAAY | |
|---|---|---|
Market Cap | $8.62B | $27.11B |
Volume | 2,594,626 | 2,427,380 |
Sector | Health | Industrials |
52-Week High | $87.26 | $73.82 |
52-Week Low | $54.76 | $51.95 |
Typical Hold Time | 19 Days | 72 Days |
Enterprise Value | $8.72B | $24.18B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
RYAAY trades at $53.05, down 5.27% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals with $13.95B revenue, 12.13% net margin, and attractive valuation at 13.43 P/E. Recent earnings show mixed results with Q2 2026 missing expectations, while analysts maintain 64.71% buy rating. The company faces headwinds from fuel costs and Boeing MAX 10 certification delays, but maintains robust cash flow and balance sheet strength.
RYAAY presents a compelling value opportunity with solid profitability and growth prospects, though near-term volatility from oil prices and operational challenges warrants caution. The stock's current discount to historical valuations combined with strong market position supports long-term upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
